BioNexus Gene Lab (NASDAQ:BGLC) Receives Sell (E+) Rating from Weiss Ratings

Weiss Ratings reissued their sell (e+) rating on shares of BioNexus Gene Lab (NASDAQ:BGLC) in a research note released on Thursday,Weiss Ratings reports.

BioNexus Gene Lab Stock Performance

NASDAQ BGLC opened at $5.19 on Thursday. The stock has a market capitalization of $9.34 million, a P/E ratio of -9.11 and a beta of 5.20. BioNexus Gene Lab has a 1 year low of $2.01 and a 1 year high of $15.60. The business’s fifty day moving average is $5.33 and its two-hundred day moving average is $4.50.

BioNexus Gene Lab (NASDAQ:BGLC) last posted its quarterly earnings results on Monday, August 18th. The company reported ($0.34) earnings per share (EPS) for the quarter. BioNexus Gene Lab had a negative net margin of 30.70% and a negative return on equity of 35.54%. The company had revenue of $2.26 million during the quarter.

BioNexus Gene Lab Company Profile

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers.